Pioneering End-to-End Green Chemical Production
Turn compliance into opportunity—see how data and innovation drive greener processes, lower costs, and sustainable growth in chemical manufacturing.
Chemistry
Bioeconomy Horizons: Transforming the Chemical Industry
The bioeconomy offers the chemical industry new pathways to resilience and sustainability—even as economic and political priorities shift
Sustainable Chemistry Meets Bioeconomy: A Perfect Match
How Sustainable Innovation Can Drive Inclusive Growth in Latin America and the Caribbean
Resetting the UK-EU Relationship
A Path to Stabilizing the Chemical Supply Chain
Standing Strong for Europe's Chemical Industry
Rising tariffs and regulatory changes challenge the European chemical industry, highlighting the need for resilient regional supply networks and strategic collaboration among CEFIC members.
Maximize the Potential of Spent Hydroprocessing Catalysts
A new approach is helping reduce waste, recover value, and deliver on sustainability goals.
Making Waves
Global water scarcity is now urgent due to climate change, population growth, and unsustainable practices. 700 million people could be displaced by 2030, warns UNICEF, especially in water-intensive industries like personal care, textiles, food production, and paint.
New Deal to Boost Competitiveness
The EU Green Deal has hurt Europe's industry. The Clean Industrial Deal aims to improve this, but a change of mindset at the Commission is needed.
Expert Statement: Frank Ferrante, Cambrex
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Flow Chemistry in Drug Discovery
For the synthesis of compounds in pharmaceutical applications, it is important to select the most appropriate flow chemistry regime and equipment based on the goals of the application.
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Minicircle DNA
The minicircle has emerged as a Next Generation Gene Vector and as a promising tool in the field of gene delivery and therapeutic applications. This overview aims to cover the characteristics, production methods, and potential applications of minicircle DNA.
Uncovering Potential
Interview with Olivier Lambrechts, executive leadership team member and president NCE at Arxada.
Expert Statement: Martin Meeson, Axplora
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Victor Swint, Formulated Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Akhil Ravi, Aurigene Pharmaceutical Services
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Yu Lu, WuXi STA
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Jordi Robinson, Navin Molecular
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Alex Del Priore, Syngene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Chad Telgenhof, Sterling Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Thomas Otto and Peter Soelkner, Vetter
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Davuluri Saharsh Rao, Neuland Labs
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Christoph Schaffrath, Lanxess
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ludwig de Mot, EuroAPI
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Frank Wegener, ESIM Chemicals
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Russel Miller, Enzene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: David McErlane and Aris Gennadios, Catalent
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Torsten Wöhr, Bachem
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
